TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37293631

Group type: EXPERIMENTAL
Intervention: Integrated package of HIV and sexual and reproductive health services including family planning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Provider experiences and perspectives
Number of subjects: 0
Study: 37294085

Group type: EXPERIMENTAL
Intervention: Lenvatinib plus pembrolizumab
Number of subjects: 213

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 213
Study: 37294089

Group type: EXPERIMENTAL
Intervention: Nudge intervention (automated reminder message for clinicians)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 222
Study: 37294101

Group type: EXPERIMENTAL
Intervention: Mindfulness-based sexual counseling (4-week, 8-session program)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 134
Study: 37294145

Group type: EXPERIMENTAL
Intervention: Multiple Electrolytes Solution (MES) (n = 351)
Number of subjects: 708

Group type: COMPARATOR
Intervention: 0.9% Saline (n = 357)
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Multiple Electrolytes Solution (MES)
Number of subjects: 708

Group type: COMPARATOR
Intervention: 0.9% Saline
Number of subjects: 708
Study: 37294245

Group type: EXPERIMENTAL
Intervention: Semaglutide (glucagon-like peptide-1 receptor agonist)
Number of subjects: 1146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1146
Study: 37294342

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus doxorubicin every 3 weeks for 6 cycles followed by pembrolizumab maintenance until disease progression or intolerance.
Number of subjects: 10
Study: 37294433

Group type: EXPERIMENTAL
Intervention: faricimab 6.0 mg Q16W
Number of subjects: 120

Group type: COMPARATOR
Intervention: aflibercept 2.0 mg Q8W
Number of subjects: 120
Study: 37294458

Group type: EXPERIMENTAL
Intervention: Primary MPS patients
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Primary MPS patients with BDI score ≥ 17
Number of subjects: 45
Study: 37294477

Group type: EXPERIMENTAL
Intervention: IV ibuprofen 10 mg/kg every 6 hours, up to four doses per day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: IV ibuprofen
Number of subjects: 24
Study: 37294569

Group type: EXPERIMENTAL
Intervention: Peer reviewers received an email to check 10 CONSORT items
Number of subjects: 510

Group type: COMPARATOR
Intervention: Usual journal practice (control group)
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Peer reviewers received an email to check 10 SPIRIT items
Number of subjects: 510
Study: 37294571

Group type: EXPERIMENTAL
Intervention: Sustained public health interventions including increased MOUD initiation by 2- or 5-fold, improved MOUD retention, increased naloxone distribution, and safe opioid prescribing.
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Sustained public health interventions for an additional 3 years.
Number of subjects: 4
Study: 37294588

Group type: EXPERIMENTAL
Intervention: Digital health platform for home hospitalization (HH)
Number of subjects: 63
Study: 37294604

Group type: EXPERIMENTAL
Intervention: Adapted interactive obesity treatment approach for 6 months
Number of subjects: 52

Group type: COMPARATOR
Intervention: Attentional control condition for 6 months
Number of subjects: 52
Study: 37294609

Group type: EXPERIMENTAL
Intervention: Health promotion intervention via a web-based community game (Habbo; Sulake Oy)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Application of 27 recommendations for intervention preparation and implementation in web-based games
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Integrated health promotion interventions in web-based community games
Number of subjects: 22
Study: 37294671

Group type: EXPERIMENTAL
Intervention: Left bundle branch pacing (LBBP)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Stepwise application of ECG and electrogram criteria
Number of subjects: 24
Study: 37294727

Group type: EXPERIMENTAL
Intervention: Pilates exercise programme (38 weeks, 2 sessions/week, 15 min/session)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 103
Study: 37294816

Group type: EXPERIMENTAL
Intervention: Veterans with a lifetime history of SA
Number of subjects: 183

Group type: COMPARATOR
Intervention: Veterans without a lifetime history of SA
Number of subjects: 183
Study: 37294823

Group type: EXPERIMENTAL
Intervention: Video-based teach-to-go intervention
Number of subjects: 103
Study: 37294843

Group type: EXPERIMENTAL
Intervention: Same-day treatment (same-day TB testing with same-day TB treatment if TB diagnosed; same-day ART if TB not diagnosed)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard care (initiating TB treatment within 7 days and delaying ART to day 7 if TB not diagnosed)
Number of subjects: 500
Study: 37294870

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 277

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Nintedanib (SENSCIS-ON)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Placebo (SENSCIS-ON)
Number of subjects: 277
Study: 37294914

Group type: EXPERIMENTAL
Intervention: Eltrombopag (starting dose of 50 mg once daily to a maximum of 300 mg)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study: 37294939

Group type: EXPERIMENTAL
Intervention: same™ device (Smart Autotransfusion for ME; i-SEP, France) used intraoperatively to treat shed and residual cardiopulmonary bypass blood.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: same™ device
Number of subjects: 50
Study: 37294948

Group type: EXPERIMENTAL
Intervention: XMT-1660 (site-specific DS DAR 6 ADC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: XMT-1660
Number of subjects: 0
Study: 37295011

Group type: EXPERIMENTAL
Intervention: Verbal Expressive Skill Management Program in Urdu (VESMP-U)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Melodic Intonation Therapy (MIT)
Number of subjects: 54
Study: 37295035

Group type: EXPERIMENTAL
Intervention: Neutralizing antibodies (NAb) transfer ratio (TR)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Male newborns
Number of subjects: 173

Group type: COMPARATOR
Intervention: NAb TR in 3rd trimester SARS-CoV-2 infected mothers
Number of subjects: 173

Group type: COMPARATOR
Intervention: NAb TR in 1st or 2nd trimester infected mothers
Number of subjects: 173
Study: 37295336

Group type: EXPERIMENTAL
Intervention: Growth Hormone Replacement Therapy (GHRT)
Number of subjects: 7
Study: 37295445

Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel) at a target dose level of 50 × 10^6 cells, administered as a single intravenous infusion.
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel)
Number of subjects: 117
Study: 37295501

Group type: EXPERIMENTAL
Intervention: Educational program guided by the Health Promotion Model
Number of subjects: 69
Study: 37295609

Group type: EXPERIMENTAL
Intervention: Lorlatinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 0
Study: 37295665

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg daily for 12 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 37295667

Group type: EXPERIMENTAL
Intervention: LVAD implantation
Number of subjects: 22
Study: 37295720

Group type: EXPERIMENTAL
Intervention: NK cell-enriched molecular rejection-like state (NKRL)
Number of subjects: 896

Group type: EXPERIMENTAL
Intervention: T cell-mediated rejection (TCMR)/Mixed
Number of subjects: 896

Group type: COMPARATOR
Intervention: No rejection
Number of subjects: 896
Study: 37295793

Group type: EXPERIMENTAL
Intervention: Interscalene block with perineural or intravenous adjuvants
Number of subjects: 477
Study: 37295810

Group type: EXPERIMENTAL
Intervention: Pipeline Embolization Device (PED) treatment
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Adjunctive coiling
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Dense embolism
Number of subjects: 218
Study: 37295816

Group type: EXPERIMENTAL
Intervention: CD22 CAR T-cells
Number of subjects: 53
Study: 37295824

Group type: EXPERIMENTAL
Intervention: Complex intervention consisting of early cooperation among GP, care manager, and rehabilitation coordinator, plus a person-centred dialogue meeting between patient and employer within 3 months.
Number of subjects: 341
Study: 37295823

Group type: EXPERIMENTAL
Intervention: Surgery for patellar instability
Number of subjects: 15
Study: 37295836

Group type: EXPERIMENTAL
Intervention: Individualised duration of antibiotic therapy (3 days after clinical improvement)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Standard duration of antibiotic therapy (10 days)
Number of subjects: 408
Study: 37296040

Group type: EXPERIMENTAL
Intervention: Prostate biopsy approach recommended by the European Association of Urology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prostate biopsy approach recommended by the American Urological Association
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current level 1 evidence
Number of subjects: 0
Study: 37296268

Group type: EXPERIMENTAL
Intervention: FACIT-Fatigue
Number of subjects: 63
Study: 37296409

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Partial breastfeeding
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: No breastfeeding
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Multiparity
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Early breastfeeding in the first hour
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Rooming-in
Number of subjects: 235
Study: 37296411

Group type: EXPERIMENTAL
Intervention: Secondary in-the-bag IOL implantation
Number of subjects: 286

Group type: COMPARATOR
Intervention: Secondary sulcus IOL implantation
Number of subjects: 286
Study: 37296413

Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise protocol, 3 days per week for 10 weeks
Number of subjects: 0
Study: 37296432

Group type: EXPERIMENTAL
Intervention: Propranolol and clonidine
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 37296456

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 439
Study: 37296463

Group type: EXPERIMENTAL
Intervention: Pyrotinib
Number of subjects: 75
Study: 37296468

Group type: EXPERIMENTAL
Intervention: short, animated storytelling intervention video on sodium as a cardiovascular disease risk factor
Number of subjects: 10000

Group type: COMPARATOR
Intervention: surveys only
Number of subjects: 10000

Group type: COMPARATOR
Intervention: attention placebo control video
Number of subjects: 10000

Group type: COMPARATOR
Intervention: exposed to neither the video nor the surveys
Number of subjects: 10000
Study: 37296922

Group type: EXPERIMENTAL
Intervention: Doxorubicin-ifosfamide chemotherapy and 5 × 5 Gy radiotherapy
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High expression of HIF-1α before surgery
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Samples after surgery with decreased expression of HIF-1α
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High expression of γH2AFX
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High number of positive-staining tumor-associated macrophages (TAMs) and high microvessel density (IMVD)
Number of subjects: 19
Study: 37296982

Group type: EXPERIMENTAL
Intervention: Jejunal tube peptide-based diet for 12 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil-based chemotherapy (e.g., FOLFIRINOX)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Gemcitabine-based chemotherapy (e.g., gemcitabine/nab-paclitaxel)
Number of subjects: 31
Study: 37297976

Group type: EXPERIMENTAL
Intervention: LigaSure device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37300312

Group type: EXPERIMENTAL
Intervention: Very high-frequency digital ultrasound (Insight 100)
Number of subjects: 40
Study: 37300484

Group type: EXPERIMENTAL
Intervention: Radioiodine therapy for thyroid cancer
Number of subjects: 0
Study: 37300573

Group type: EXPERIMENTAL
Intervention: Intratumoral hypoxia imaging
Number of subjects: 16
Study: 37300632

Group type: EXPERIMENTAL
Intervention: Enhanced envelope (padded with tracking label and colored messaging sticker)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Plain envelope
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Overall clinic-level screening
Number of subjects: 316
Study: 37300760

Group type: EXPERIMENTAL
Intervention: dupilumab + TCS
Number of subjects: 304

Group type: COMPARATOR
Intervention: placebo + TCS
Number of subjects: 304
Study: 37300792

Group type: EXPERIMENTAL
Intervention: GN-037 cream applied topically twice daily for 2 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo applied topically twice daily for 2 weeks
Number of subjects: 18
Study: 37300882

Group type: EXPERIMENTAL
Intervention: Early achievement of energy targets (EAET)
Number of subjects: 635
Study: 37300888

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Upfront resection (UR)
Number of subjects: 159

Group type: COMPARATOR
Intervention: UR without adjuvant chemotherapy
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Overall survival in NAC
Number of subjects: 159

Group type: COMPARATOR
Intervention: Overall survival in UR
Number of subjects: 159

Group type: COMPARATOR
Intervention: Overall survival in UR without adjuvant chemotherapy
Number of subjects: 159
Study: 37301192

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 168
Study: 37301468

Group type: EXPERIMENTAL
Intervention: HPV ECHO (AAT to providers)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: HPV ECHO+ (AAT to providers plus recall notices to vaccine-declining parents)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 36
Study: 37301552

Group type: EXPERIMENTAL
Intervention: Paraspinal muscle contraction
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Relaxed paraspinal muscles
Number of subjects: 30

Group type: COMPARATOR
Intervention: 4-week no manual therapy period
Number of subjects: 30
Study: 37301631

Group type: EXPERIMENTAL
Intervention: Zevalin (ibritumomab tiuxetan) combined with reduced intensity conditioning (RIC) regimen of fludarabine and melphalan (Flu/Mel)
Number of subjects: 41
Study: 37301653

Group type: EXPERIMENTAL
Intervention: Rose oil aromatherapy
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Hand-holding
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 126
Study: 37301758

Group type: EXPERIMENTAL
Intervention: Copayment assistance intervention
Number of subjects: 6212

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6212
Study: 37301762

Group type: EXPERIMENTAL
Intervention: 3-hydroxybutyrate (3-OHB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Niacin
Number of subjects: 0
Study: 37301768

Group type: EXPERIMENTAL
Intervention: Intensive antihypertensive treatment
Number of subjects: 289

Group type: COMPARATOR
Intervention: Standard antihypertensive treatment
Number of subjects: 289
Study: 37301841

Group type: EXPERIMENTAL
Intervention: PRISMS (Patient Reported Outcomes-Informed Symptom Management System)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 23
Study: 37301885

Group type: EXPERIMENTAL
Intervention: Neo-T therapy with lymphodepletion
Number of subjects: 9

Group type: COMPARATOR
Intervention: Neo-T therapy without lymphodepletion
Number of subjects: 9
Study: 37301934

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 60
Study: 37301974

Group type: EXPERIMENTAL
Intervention: Immediate kangaroo mother care (iKMC)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 5
Study: 37302039

Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel (LCIG)
Number of subjects: 0
Study: 37302134

Group type: EXPERIMENTAL
Intervention: MANTRa (24-34 individual sessions)
Number of subjects: 92

Group type: COMPARATOR
Intervention: TAU-O (standard individual psychotherapy)
Number of subjects: 92
Study: 37302348

Group type: EXPERIMENTAL
Intervention: Co-morbid CVD/CVRF
Number of subjects: 10876

Group type: EXPERIMENTAL
Intervention: CVD/CVRF
Number of subjects: 10876

Group type: EXPERIMENTAL
Intervention: Not receiving active cancer therapy
Number of subjects: 10876

Group type: EXPERIMENTAL
Intervention: COVID-19 related cardiovascular complications
Number of subjects: 10876
Study: 37302393

Group type: EXPERIMENTAL
Intervention: pyrotinib, trastuzumab, docetaxel, and carboplatin
Number of subjects: 69

Group type: COMPARATOR
Intervention: placebo, trastuzumab, docetaxel, and carboplatin
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: pyrotinib
Number of subjects: 69

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 69
Study: 37302406

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 1323

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1323
Study: 37302449

Group type: EXPERIMENTAL
Intervention: CurQD (curcumin-QingDai) 3 g/d for 8 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: CurQD (curcumin-QingDai) maintenance after 8 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 42
Study: 37302513

Group type: EXPERIMENTAL
Intervention: Pathways to Freedom Video
Number of subjects: 1053

Group type: COMPARATOR
Intervention: Standard Video
Number of subjects: 1053

Group type: COMPARATOR
Intervention: Quitline Services Only
Number of subjects: 1053
Study: 37302533

Group type: EXPERIMENTAL
Intervention: Psilocybin-assisted group therapy (25 mg high-dose session)
Number of subjects: 12
Study: 37302544

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study: 37302573

Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 37302651

Group type: EXPERIMENTAL
Intervention: Surgical myectomy
Number of subjects: 173
Study: 37302712

Group type: EXPERIMENTAL
Intervention: Oral treatment with ovalbumin (OVA) in obese mice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperglycemia treatment in obese mice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment with a hypoglycemic drug in obese mice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of serum IgE levels in individuals with T2D
Number of subjects: 0
Study: 37302737

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation over 5 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37302738

Group type: EXPERIMENTAL
Intervention: Concomitant left atrial appendage (LAA) closure during open-heart surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no LAA closure)
Number of subjects: 0
Study: 37302963

Group type: EXPERIMENTAL
Intervention: Mini-dose esketamine-dexmedetomidine combination
Number of subjects: 200

Group type: COMPARATOR
Intervention: Patient-controlled sufentanil analgesia (4 μg kg)
Number of subjects: 200
Study: 37303003

Group type: EXPERIMENTAL
Intervention: BIA method for calculating CM dose
Number of subjects: 89

Group type: COMPARATOR
Intervention: TBW method for calculating CM dose
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Lean body weight using BIA
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Lean body weight BIA protocol
Number of subjects: 89
Study: 37303034

Group type: EXPERIMENTAL
Intervention: Erenumab
Number of subjects: 751
Study: 37303073

Group type: EXPERIMENTAL
Intervention: Pupillometry measures (PUAL and PLR)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Numeric Rating Scale (NRS) for self-reported pain intensity
Number of subjects: 313
Study: 37303085

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 37303083

Group type: EXPERIMENTAL
Intervention: Biomarkers of Kidney Tubule Health, Injury, and Inflammation
Number of subjects: 0
Study: 37303153

Group type: EXPERIMENTAL
Intervention: Mechanical hippotherapy group (MHG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 37303618

Group type: EXPERIMENTAL
Intervention: Virtual reality headset pain education and mindfulness intervention
Number of subjects: 20
Study: 37303683

Group type: EXPERIMENTAL
Intervention: Aspirin plus clopidogrel and rt-PA intravenous thrombolytic therapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Aspirin plus clopidogrel
Number of subjects: 76
Study: 37303805

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Entecavir (ETV)
Number of subjects: 272
Study: 37304043

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Ranibizumab 2.0 mg
Number of subjects: 502

Group type: COMPARATOR
Intervention: Benchmark linear model of baseline age and BCVA
Number of subjects: 502
Study: 37304164

Group type: EXPERIMENTAL
Intervention: Initial PRGS ≤ 2
Number of subjects: 97

Group type: COMPARATOR
Intervention: Initial PRGS ≥ 3
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Histological response (defined as lower or stable mean PRGS)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Progression (defined as increasing mean PRGS)
Number of subjects: 97
Study: 37304207

Group type: EXPERIMENTAL
Intervention: Technology-Assisted Language Intervention (TALI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 0
Study: 37304432

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (FLV) treatment for 2 months
Number of subjects: 65
Study: 37304498

Group type: EXPERIMENTAL
Intervention: Day Care Approach (DCA)
Number of subjects: 3211

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 3211

Group type: EXPERIMENTAL
Intervention: DCA
Number of subjects: 3211

Group type: COMPARATOR
Intervention: UC
Number of subjects: 3211
Study: 37304494

Group type: EXPERIMENTAL
Intervention: INSTI + DRV/r (Dolutegravir or Elvitegravir)
Number of subjects: 318

Group type: COMPARATOR
Intervention: SOC (2NRTI + boosted PI/NNRTI)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: INSTI + DRV/r
Number of subjects: 318

Group type: COMPARATOR
Intervention: SOC
Number of subjects: 318